AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

938.989

+6.7180.72%

Number of Gainers:14

Number of Losers:11

Number of Flat:20

PE:- -

High:945.090

Open:940.859

Low:935.051

Close:932.271

Volume:37.73M

Turnover:76.39M

Market Cap:142.20B

Float Cap:139.39B

Loading ...

The only 3 Australian stocks I'd hold forever

ASX Penny Stock Insights Featuring Duratec And 2 More

Simply Wall St.

Immuron Limited CEO Steven Lydeamore to Present at Emerging Growth Conference

BMW Invests Over €30 Million in New Custom Paint Center at Dingolfing Plant

Anatara Lifesciences Ltd-Appendix 4E & Financial Report 30 June 2025

THOMSON REUTERS

How Investors May Respond To CSL (ASX:CSL) Gaining Canadian Approval for ANDEMBRY in Rare Disease Market

Simply Wall St.

Should you buy the rebound in CSL shares today?

Orthocell Lodges Hospital Value Assessment Committee Applications in US for Nerve Repair Product

MT Newswires Live

Why This ASX 200 Stock Could Jump 25%

BRIEF-Anteotech Executes Commission Agency Agreement With Kangshin Industrial Co

Imugene Ltd-Update - Proposed Issue of Securities - Imu

THOMSON REUTERS

Anteotech Ltd-Appointment of South Korean Distributor

THOMSON REUTERS

Here's Why We're Watching Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Simply Wall St.

Stablecoin Issuer Paxos Applies to U.S. OCC for Trust Bank Charter

Dimerix's Potential US FDA Approval Can Add AU$119 Million in Development Milestone Payments, Says Euroz Hartleys

MT Newswires Live

CSL Shares Rise Upon Receipt of Canada Marketing Approval

MT Newswires Live

Noxopharm Advances HERACLES Trial as Sofra Platform Gains US Momentum

Noxopharm Ltd-Heracles Clinical Trial Update 2

THOMSON REUTERS

Where to invest $10,000 in Australian shares in August

How to turn small ASX investments into life-changing wealth

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":938.9887,"timestamp":1755143581251,"preClose":932.2707,"halted":0,"volume":37725191,"delay":0,"changeRate":0.007206,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":6.718018,"latestTime":"08-14 13:53:01 AEST","open":940.85864,"high":945.09033,"low":935.0506,"amount":76393471,"amplitude":0.010769,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1755151200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1755129600000,1755151200000]],"turnoverRate":0.001351,"increases":15,"decrements":11,"flats":18,"marketCap":142197189166.875,"floatMarketCap":139385941843.125},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":945.09033,"amplitude":0.010769,"preClose":932.2707,"low":935.0506,"latestPrice":938.9887,"volume":37725191,"delay":0,"open":940.85864,"prevYearClose":936.801,"prevWeekClose":905.196,"prevMonthClose":933.602,"prevQuarterClose":795.022,"fiveDayClose":920.82,"twentyDayClose":841.623,"sixtyDayClose":814.514,"secType":"PLATE","market":"AU","turnoverRate":0.001351,"marketCap":142197189166.875,"floatMarketCap":139385941843.125,"timestamp":1755143581251,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":14,"down":11,"flat":20},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2559989733","title":"The only 3 Australian stocks I'd hold forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2559989733","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559989733?lang=en_us&edition=fundamental","pubTime":"2025-08-14 03:23","pubTimestamp":1755112980,"startTime":"0","endTime":"0","summary":"Some companies are worth buying and never selling. They operate in industries with strong long-term demand, have durable competitive advantages, and can reinvest profits to keep growing year after yea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/08/14/the-only-3-australian-stocks-id-hold-forever/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7501","CSL.AU","BK7503","XJO.AU","RMD.AU","XAO.AU","BK7067","XKO.AU","BK7016","WTC.AU","BK7508","BK7007","BK7511"],"gpt_icon":0},{"id":"2559981046","title":"ASX Penny Stock Insights Featuring Duratec And 2 More","url":"https://stock-news.laohu8.com/highlight/detail?id=2559981046","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559981046?lang=en_us&edition=fundamental","pubTime":"2025-08-14 03:02","pubTimestamp":1755111730,"startTime":"0","endTime":"0","summary":"The Australian market has seen a mixed performance recently, with sectors like Health Care and Materials showing resilience despite broader challenges in Utilities and Financials. In such fluctuating conditions, identifying stocks with strong financial foundations becomes crucial for investors seeking stability and growth. Penny stocks, while sometimes perceived as outdated, can still offer valuable opportunities when backed by solid fundamentals; this article will explore three such...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-dur/duratec-shares/news/asx-penny-stock-insights-featuring-duratec-and-2-more","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CLX.AU","BK7007","BK7055","GNG.AU","BK7501","BK7077","BK7129","BK7506","SPL.AU","BK7096","EZZ.AU","IGL.AU","BK7104","ANG.AU","WAF.AU","BK7062","GTN.AU","AAL.AU","RPL.AU","AHC.AU","BIS.AU","DUR.AU","BK7048","BK7058","BK7508","BK7045","BK7095"],"gpt_icon":0},{"id":"2559601051","title":"Immuron Limited CEO Steven Lydeamore to Present at Emerging Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2559601051","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559601051?lang=en_us&edition=fundamental","pubTime":"2025-08-13 19:55","pubTimestamp":1755086158,"startTime":"0","endTime":"0","summary":"Immuron Limited's CEO, Steven Lydeamore, will present at the Emerging Growth Conference on Wednesday, August 20, 2025, from 9:05am to 9:35am U.S. Eastern Time. The presentation will be conducted virtually, and Mr. Lydeamore may open the floor for questions following his presentation. Attendees are encouraged to submit questions in advance or during the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 13, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDLxBcLV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2559705836","title":"BMW Invests Over €30 Million in New Custom Paint Center at Dingolfing Plant","url":"https://stock-news.laohu8.com/highlight/detail?id=2559705836","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559705836?lang=en_us&edition=fundamental","pubTime":"2025-08-13 16:01","pubTimestamp":1755072089,"startTime":"0","endTime":"0","summary":"BMW is set to expand its capabilities with a new \"Center for Special and Individual Paints\" at its Dingolfing plant. The company is investing over 30 million euros to extend the existing vehicle paint shop, with construction beginning in September 2025 and production expected to start in spring 2027. The expansion will cover over 2,000 square meters and feature two work levels, allowing for a greater number of bespoke customer requests and special paint jobs to be processed more efficiently. Customers currently have the option to choose from up to 300 different paint colors, including unique two-tone designs and special coatings for limited editions such as the BMW 3.0 CSL and BMW M4 CS Edition VR46. The new facility is projected to employ a low double-digit number of staff, reducing processing time by roughly a quarter and lowering production costs. The drying process in the new area will utilize electricity rather than natural gas, aligning with energy-efficient practices. The facili","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDLc7ysbM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7511","BK7501","BK7508","BK7067"],"gpt_icon":0},{"id":"2559728676","title":"Anatara Lifesciences Ltd-Appendix 4E & Financial Report 30 June 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2559728676","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559728676?lang=en_us&edition=fundamental","pubTime":"2025-08-13 14:48","pubTimestamp":1755067715,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nTUE8CQBQG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ANR.AU","BK7508"],"gpt_icon":0},{"id":"2559606245","title":"How Investors May Respond To CSL (ASX:CSL) Gaining Canadian Approval for ANDEMBRY in Rare Disease Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2559606245","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559606245?lang=en_us&edition=fundamental","pubTime":"2025-08-13 14:45","pubTimestamp":1755067508,"startTime":"0","endTime":"0","summary":"CSL recently announced that Health Canada granted marketing authorization for ANDEMBRY (garadacimab), a monoclonal antibody for the routine prevention of hereditary angioedema attacks in patients aged 12 years and older.\nThis regulatory milestone gives CSL access to the Canadian HAE market with a product that showed very large reductions in attack frequency and sustained safety in pivotal studies.\nWe'll examine how ANDEMBRY's approval in Canada could strengthen CSL's position and growth...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/how-investors-may-respond-to-csl-asxcsl-gaining-canadian-app","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0728928796.USD","ISBC","BK4086","CSL","SGXZ23171101.USD","BK4211","LU1169590202.USD","SG9999004303.SGD","BK7501","BK7511","LU1169589451.USD","CSL.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2559676252","title":"Should you buy the rebound in CSL shares today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2559676252","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559676252?lang=en_us&edition=fundamental","pubTime":"2025-08-13 11:48","pubTimestamp":1755056902,"startTime":"0","endTime":"0","summary":"CSL Ltd  shares are shaking off the broader selling action today and marching higher. Shares in the S&P/ASX 200 Index biotech stock closed yesterday trading for $264.31. At the time of writing on Wednesday afternoon, shares are changing hands for $269.41 apiece, up 1.9%. For some context, the ASX 200 is down 0.5% at this same time. With today's intraday gains factored in, CSL stock is now up more than 15% since the recent closing lows on 27 June. Over the past full year, however, CSL has underperformed the benchmark index, sinking 8.5% compared to the 12.9% one-year gain posted by the ASX 200. Though that performance doesn't include the  $4.25 in unfranked dividends CSL paid eligible stockholders over the full year. At the current price, CSL shares trade on an unfranked trailing dividend yield of 1.6%. Which brings us back to our headline question. CSL shares: Buy, hold, or sell?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/08/13/should-you-buy-the-rebound-in-csl-shares-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU0728928796.USD","CSL.AU","BK7508","LU1169590202.USD","BK4086","LU1169589451.USD","CSL","BK7067","BK7511","BK7501","SGXZ23171101.USD","XJO.AU","SG9999004303.SGD"],"gpt_icon":0},{"id":"2559383678","title":"Orthocell Lodges Hospital Value Assessment Committee Applications in US for Nerve Repair Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2559383678","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559383678?lang=en_us&edition=fundamental","pubTime":"2025-08-13 08:44","pubTimestamp":1755045891,"startTime":"0","endTime":"0","summary":"Orthocell (ASX:OCC) said 10 surgeries have taken place in the US using its nerve repair product, Remplir, and it lodged 36 applications to hospital value assessment committees with three approvals alr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2558769540","title":"Why This ASX 200 Stock Could Jump 25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558769540","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558769540?lang=en_us&edition=fundamental","pubTime":"2025-08-12 13:20","pubTimestamp":1754976005,"startTime":"0","endTime":"0","summary":"Looking for some exposure to the healthcare sector?If you are, it could be worth considering the ASX 200 stock in this article. That's because Bell Potter believes that its shares could generate big returns over the next 12 months. Which ASX 200 stock?","market":null,"thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/08/12/why-this-asx-200-stock-could-jump-25/","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7096","BK4139","BK4135","LU2065171311.SGD","NEU.AU","LU2065170008.USD","LU2065169927.USD","LU2065171402.SGD","BK7508"],"gpt_icon":0},{"id":"2558314694","title":"BRIEF-Anteotech Executes Commission Agency Agreement With Kangshin Industrial Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2558314694","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558314694?lang=en_us&edition=fundamental","pubTime":"2025-08-12 09:31","pubTimestamp":1754962298,"startTime":"0","endTime":"0","summary":"BRIEF-Anteotech Executes Commission Agency Agreement With Kangshin Industrial CoAug 12 (Reuters) - Anteotech Ltd ADO.AX:APPOINTMENT OF SOUTH KOREAN DISTRIBUTOREXECUTES COMMISSION AGENCY AGREEMENT WITH KANGSHIN INDUSTRIAL COFurther company coverage: ADO.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nTUE70LPFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","BK7036","BK7501","ADO.AU","BK7508"],"gpt_icon":0},{"id":"2558696573","title":"Imugene Ltd-Update - Proposed Issue of Securities - Imu","url":"https://stock-news.laohu8.com/highlight/detail?id=2558696573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558696573?lang=en_us&edition=fundamental","pubTime":"2025-08-12 07:27","pubTimestamp":1754954839,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nTUE3M5DBX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMU.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2558696351","title":"Anteotech Ltd-Appointment of South Korean Distributor","url":"https://stock-news.laohu8.com/highlight/detail?id=2558696351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558696351?lang=en_us&edition=fundamental","pubTime":"2025-08-12 07:17","pubTimestamp":1754954249,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nTUE70LPFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","BK7048","BK7036","ADO.AU"],"gpt_icon":0},{"id":"2558461923","title":"Here's Why We're Watching Starpharma Holdings' (ASX:SPL) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2558461923","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558461923?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:00","pubTimestamp":1754942450,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-spl/starpharma-holdings-shares/news/heres-why-were-watching-starpharma-holdings-asxspl-cash-burn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SPL.AU","BK7096","BK7501","BK7508"],"gpt_icon":0},{"id":"2558661455","title":"Stablecoin Issuer Paxos Applies to U.S. OCC for Trust Bank Charter","url":"https://stock-news.laohu8.com/highlight/detail?id=2558661455","media":"Blockbeats","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558661455?lang=en_us&edition=fundamental","pubTime":"2025-08-11 22:53","pubTimestamp":1754923980,"startTime":"0","endTime":"0","summary":"BlockBeats News, August 11th, according to market sources, stablecoin issuer Paxos stated that it is applying for a Trust Bank charter with the US Office of the Comptroller of the Currency (OCC) and plans to open an office in the United States to expand its regulated financial services.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/306898","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["OCC","BK4211","BK7067","UBCP","BK4020","OCC.AU","BK7508"],"gpt_icon":0},{"id":"2558763173","title":"Dimerix's Potential US FDA Approval Can Add AU$119 Million in Development Milestone Payments, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2558763173","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558763173?lang=en_us&edition=fundamental","pubTime":"2025-08-11 14:30","pubTimestamp":1754893854,"startTime":"0","endTime":"0","summary":"Dimerix's  potential successful interim readout could allow accelerated approval of DMX-200 in Focal Segmental Glomerulosclerosis, enabling US sales to start in the second half of calendar 2026, said Euroz Hartleys in a Monday note.The research firm noted that the company's US entry would significantly reduce its regulatory risk, as under its US licensing deal with Amicus Therapeutics, success might unlock up to AU$119 million in development milestone payments, equivalent to around AU$0.20 per share in cash.The research firm also noted that an additional AU$709 million could be earned in commercial milestone payments, and it would also receive tiered royalties in the low-teen to low-twenties percentage range based on US net sales.Euroz Hartleys has maintained its speculative buy recommendation with a price target of AU$1.68.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7067","DXB.AU","BK7508"],"gpt_icon":0},{"id":"2558687948","title":"CSL Shares Rise Upon Receipt of Canada Marketing Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2558687948","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558687948?lang=en_us&edition=fundamental","pubTime":"2025-08-11 08:44","pubTimestamp":1754873054,"startTime":"0","endTime":"0","summary":"CSL  shares rose nearly 1% in morning trade Monday after the biotechnology company secured marketing authorization from Health Canada for Andembry as a once-monthly treatment for hereditary angioedema attacks in adult and pediatric patients aged 12 years and older.Andembry is designed to target activated FXII, a plasma protein that plays a key role in the attacks, according to the company's Friday, Aug. 8 release.Hereditary angioedema is a rare and potentially life-threatening genetic disorder characterized by recurrent and unpredictable attacks of swelling in various parts of the body.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999004303.SGD","BK7501","BK7508","CSL","BK7511","BK7067","SGXZ23171101.USD","LU0728928796.USD","CSL.AU","BK4086","LU1169589451.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2558168052","title":"Noxopharm Advances HERACLES Trial as Sofra Platform Gains US Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2558168052","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558168052?lang=en_us&edition=fundamental","pubTime":"2025-08-11 08:42","pubTimestamp":1754872926,"startTime":"0","endTime":"0","summary":"Noxopharm  has successfully completed the second dosing cohort in its first-in-human HERACLES trial for novel autoimmune drug candidate SOF-SKN.The safety steering committee confirmed the dose level was safe and tolerable, enabling the study to progress to a higher concentration in the next cohort.The company also reported promising preclinical results from a US collaboration that could extend the reach of its Sofra technology into cancer and inflammatory disease markets.The HERACLES trial is evaluating SOF-SKN, a topical oligonucleotide-based therapy designed to treat autoimmune diseases such as cutaneous lupus erythematosus .Conducted in Australia, the study’s first phase involves four escalating single-dose cohorts, each with four participants.The stepwise design aims to minimise patient risk while identifying an optimal dose for later-stage trials.Each two-week cohort undergoes extensive testing and monitoring, with data reviewed by the safety steering committee before approval is ","market":"nz","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/08/Noxopharm-ASX-NOX-Advances-HERACLES-Trial-Sofra-Platform-US-Momentum.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/08/Noxopharm-ASX-NOX-Advances-HERACLES-Trial-Sofra-Platform-US-Momentum.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/noxopharm-advances-heracles-trial-sofra-platform-us-momentum/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["NOX.AU","BK7501","CLE.AU","BK7067","BK7095","BK7508"],"gpt_icon":0},{"id":"2558880682","title":"Noxopharm Ltd-Heracles Clinical Trial Update 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2558880682","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558880682?lang=en_us&edition=fundamental","pubTime":"2025-08-11 06:31","pubTimestamp":1754865078,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250810:nTUE3HBR5K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7501","NOX.AU"],"gpt_icon":0},{"id":"2558068317","title":"Where to invest $10,000 in Australian shares in August","url":"https://stock-news.laohu8.com/highlight/detail?id=2558068317","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558068317?lang=en_us&edition=fundamental","pubTime":"2025-08-10 04:35","pubTimestamp":1754771700,"startTime":"0","endTime":"0","summary":"If you've got $10,000 ready to invest in the share market this month, the ASX is offering no shortage of opportunities. But which high-quality Australian shares could be buys right now?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/08/10/where-to-invest-10000-in-australian-shares-in-august/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XJO.AU","BK7503","CSL.AU","XKO.AU","XAO.AU","BK7016","BK7508","BK7511","BK7501","NXT.AU","SDR.AU","BK7043","BK7067"],"gpt_icon":0},{"id":"2558001945","title":"How to turn small ASX investments into life-changing wealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2558001945","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558001945?lang=en_us&edition=fundamental","pubTime":"2025-08-10 03:15","pubTimestamp":1754766941,"startTime":"0","endTime":"0","summary":"Investing in the share market doesn't have to start with a fortune. In fact, many of Australia's most successful long-term investors began with small, regular contributions that compounded into meaningful wealth over time.If you're wondering how to turn a modest investment habit into a portfolio that could change your financial future, here's how to get started on the ASX.The most important step in building wealth is to start — even if it is with just $500 or $1,000. Modern online brokers and micro-investing apps make it easier than ever to buy ASX shares and exchange-traded funds  with minimal upfront capital.One ASX share with a proven record of delivering long-term growth is CSL Ltd , which is a global biotech leader with a history of compounding earnings through innovation and international expansion.Finally, WiseTech Global Ltd  is a third ASX share that has created significant wealth for long term shareholders. It is a logistics software company leveraging the global shift to dig","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/08/10/how-to-turn-small-asx-investments-into-life-changing-wealth/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["FDN","VAS.AU","BK7511","BK4550","BK7503","BK7508","BK7016","BK4585","BK7501","CSL.AU","NDQ.AU","RMD.AU","BK7007","WTC.AU","BK4588","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":62,"code":"91000000","status":"200"}]}}